23643-36-9

Basic information

• Product Name: 2'-C-Methyl-, 2',3',5'-tribenzoateuridine
• Synonyms: 2'-C-Methyl-, 2',3',5'-tribenzoateuridine;2'-C-Methyl -2',3',5'-tri-O-benzoyluridine;1-(2,3,5-Tri-O-benzoyl-2-C-Methyl-β-D-ribofuranosyl)uracil;2'-C-Methyluridine 2',3',5'-tribenzoate;1-(2,3,5-Tri-O-benzoyl-2-C-methyl-beta-D-ribofuranosyl)-2,4(1H,3H)-pyrimidinedione;2'--C-Methyl-2',3',5'-tribenzoyluridine;(2R,3R,4R,5R)-5-((benzoyloxy)methyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-methyltetrahydrofuran-3,4-diyl dibenzoate
• CAS NO: 23643-36-9
• Molecular Formula: C₃₁H₂₆N₂O₉
• Molecular Weight: 570.54614
• Mol File: 23643-36-9.mol
• Article Data: 12

Chemical Properties

• Melting Point: 201-202 °C
• Appearance: /
• Density: 1.42±0.1 g/cm3(Predicted)
• PKA: 9.39±0.10(Predicted)
• CAS DataBase Reference: 2'-C-Methyl-, 2',3',5'-tribenzoateuridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-C-Methyl-, 2',3',5'-tribenzoateuridine(23643-36-9)
• EPA Substance Registry System: 2'-C-Methyl-, 2',3',5'-tribenzoateuridine(23643-36-9)

Safety Data

• Hazardous Substances Data: 23643-36-9(Hazardous Substances Data)

Usage

General Description

2'-C-Methyl-, 2',3',5'-tribenzoateuridine is a synthetic chemical compound that has been modified from the natural nucleoside uridine. It is characterized by the addition of a 2'-C-methyl group and three benzoyl groups at the 2', 3', and 5' positions. This modified uridine derivative has gained attention in the field of medicinal chemistry and drug development due to its potential therapeutic applications, particularly in the development of antiviral and anticancer agents. The chemical modification of uridine alters its biological properties, making it a promising candidate for the development of novel pharmaceuticals with improved stability, efficacy, and bioavailability. Further research and testing are needed to explore the pharmacological properties and therapeutic potential of 2'-C-Methyl-, 2',3',5'-tribenzoateuridine.

Upstream product

• 66-22-8 uracil 
• 15397-15-6 1,2,3,5-tetra-O-benzoyl-2-C-methyl-β-D-ribofuranose 
• 15397-15-6 1,2,3,5-Tetra-O-benzoyl-2-C-methyl-α(β)-D-ribofuranose 
• 3442-82-8 1,3-bis(trimethylsilyl)uracil 
• 98-88-4 benzoyl chloride 
• 69339-86-2 1,2,3,5-tetra-O-benzoyl-α-D-ribofuranoside 
• 729596-46-7 3,5-di-O-benzoyl-2-C-methyl-D-ribono-γ-lactone 
• 30361-18-3 3,5-dibenzoyloxy-2-C-methy-β-D-ribofuranose 
• 7392-74-7 (3R,4R,5R)-5-((benzoyloxy)methyl)-3-methyl-2-oxotetrahydrofuran-3,4-diyl dibenzoate 
• 492-30-8 2-C-methyl-D-ribono-1,4-lactone 
• 157037-56-4 1,3,5-tri-O-benzoyl-2-oxo-α-D-erythro-pentofuranose 

Downstream Products

• 31448-54-1 2'-C-methyluridine 
• 640725-70-8 3'-O-[N-(tert-butoxycarbonyl)-L-valinyl]-2'-C-methyl-β-D-cytidine 
• 20724-73-6 2'-C-methylcytidine 
• 115494-53-6 2'-deoxy-2'-C-β-methylcytidine 
• 115494-59-2 2'-deoxy-2'-C-α-methylcytidine 
• 159534-54-0 3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-2'-C-β-methyluridine 
• 151384-15-5 1-((2R,3S,4S,5R)-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 151384-13-3 1-((2R,3R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 596112-06-0 2'-deoxy-2'-C-β-methyl-N⁴-benzoylcytidine 
• 596112-05-9 3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-2'-deoxy-2'-C-β-methyl-N⁴-benzoylcytidine 
• 596112-07-1 5'-O-(dimethoxytrityl)-2'-deoxy-2'-C-β-methyl-N⁴-benzoylcytidine 
• 1373310-57-6 5-bromo-1-(2'-methyl-2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-1H-pyrimidine-2,4-dione 
• 944476-43-1 C₂₄H₂₀N₂O₇ 

Relevant articles and documents

Synthesis process of (2R')-2'-deoxyl-2'-fluoro-2'-methyluridine

The invention discloses a synthesis process of (2R')-2'-deoxyl-2'-fluoro-2'-methyluridine, relates to the technical field of synthesis of medicines, and solves the technical problems of high cost andlow product yield of the existing process. According to the synthesis process, sodium borohydride or potassium borohydride is used for reducing ribose lactone, so that an expensive reductive reagent which is sodium dihydro-bis-(2-methoxyethoxy)aluminate or lithium tri-tert-butoxyaluminum hydride is not used, and the cost is greatly reduced; N,O-bis(trimethylsilyl)acetamide is used as a silicon etherification reagent, so that the yield of glycosylation reaction is increased; the product yield can reach 85-90% and is far higher than that in route III by 58%; the product yield is obviously increased; hydroxyl at the 5' site is protected, so that side reaction in ring-closing reaction can be avoided; meanwhile, a common polar solvent which is dimethylformamide is used; the product yield undercatalysis of sodium hydrogen carbonate can reach 87-92%. The synthesis process is easy to operate; the process condition is more easily controlled; the cost is reduced; the synthesis process is applicable to large-batch production.

A (2 'R) -2' - deoxy -2 '- fluoro -2' - methyl urea glucoside preparation method (by machine translation)

The invention discloses a (2 'R) -2' - deoxy -2 '- fluoro -2' - methyl urea glucoside (type I) synthetic method. Cheap and easily available starting material, through the hydroxyl protection, cyclization, the links such as fluoride, obtains the type I compound. (by machine translation)

NMR-based conformational analysis of 2′,6-disubstituted uridines and antiviral evaluation of new phosphoramidate prodrugs

Six novel phosphoramidate prodrugs of uridine analogues, with structural modifications introduced at the 6- and 2′,6-positions, have been prepared and evaluated for selective antiviral activity against hepatitis C virus, as well as other positive-stranded RNA viruses. An analysis of the conformational properties of the parent nucleosides was carried out using two-dimensional NMR spectroscopy based experiments, highlighting a 3′-endo (North) sugar puckering preference and syn orientation.